At present, the main ALK fusion gene found in lung cancer is EML4 fusion ALK, which accounts for about 4% and 7%, which has been proved to be an independent and key molecular target in the occurrence and development of NSCLC.[6,7] With the development of gene sequencing technology, more and more atypical ALK fusion genes have been detected. This evidence concerns the gene EML4 and lung carcinoma.